



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

AHR agonist 3

Cat. No.:	HY-W338764
CAS No.:	23749-58-8
Molecular Formula:	C ₁₈ H ₁₀ N ₂ O
Molecular Weight:	270.28
Target:	Apoptosis; Aryl Hydrocarbon Receptor
Pathway:	Apoptosis; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (37.00 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.6999 mL	18.4993 mL	36.9987 mL
	5 mM		0.7400 mL	3.6999 mL	7.3997 mL
	10 mM		0.3700 mL	1.8499 mL	3.6999 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research^[1].

In Vitro

AHR agonist 3 (Analog 523) (10 nM; 24 hour or 2-3 weeks) induces cell cycle arrest and inhibits clonogenicity in AhR WT and AhR KO MDA-MB-468 cells ^[1].

AHR agonist 3 (0-10 μM; 48-72 hours) drives AhR-dependent apoptosis and growth inhibition in breast cancerous cells, but not normal breast epithelial cells or on-tumorigenic cells and inhibits TNBC stem cell growth via AhR.^[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	AhR WT and AhR KO MDA-MB-468 cells
Concentration:	10 nM

Incubation Time:	24 hours or 2–3 weeks
Result:	Induced an AhR-dependent S+G2/M phase arrest for Short-term (24 h) treatment. Completely exhibited the clonogenicity of AhR expressing cells while exhibiting a minimal impact on AhR deficient cells.

Apoptosis Analysis^[1]

Cell Line:	MDA-MB-468 cells, MCF10A, HEK293T and normal primary human fibroblast
Concentration:	0-10 μ M
Incubation Time:	48-72 hours
Result:	Human mammary epithelial cells (HMECs), nonmalignant mammary epithelial line Induced AhR-dependent apoptosis and growth inhibition in cancerous but not normal cells. Inhibited TNBC stem cell growth via AhR.

REFERENCES

[1]. Elson DJ, et.al. Induction of Aryl Hydrocarbon Receptor-Mediated Cancer Cell-Selective Apoptosis in Triple-Negative Breast Cancer Cells by a High-Affinity Benzimidazoisoquinoline. ACS Pharmacol Transl Sci. 2023 Jun 7;6(7):1028-1042.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA